malaria

Sanofi CEO Paul Hudson announced on Tuesday the creation of a nonprofit unit, Sanofi Global Health, which will provide 40 lower-income countries with access to 30 of the company’s “most essential medicines,” including cardiovascular, diabetes, tuberculosis, malaria and cancer treatments.

An accompanying press release said Sanofi Global Health will be the cornerstone of the Paris-based company’s corporate social responsibility strategy for “access to medicines, support for vulnerable…

Japan’s Global Health Innovative Technology Fund announced $21 million in product development investments on Wednesday.

More than two-thirds of the awards will help advance six ongoing projects, while the rest fund four new investments: a leishmaniasis drug from Takeda and the Drugs for Neglected Diseases initiative; a malaria therapy from Eisai, the Medicines for Malaria Venture and the University of Dundee; a tuberculosis drug from Daiichi Sankyo RD Novare and the TB Alliance; and a…

Portland-based Hemex Health announced Monday that its Gazelle Malaria one-minute point-of-care test outperforms current rapid diagnostic tests (RDTs) and is “nearly as accurate” as expert microscopy in detecting P. vivax malaria.

The press release referenced trial results from Brazil published last week in Malaria Journal: compared to optical microscopy, the battery-powered Gazelle test achieved 96.2% sensitivity versus 83.9% sensitivity for RDTs, according to the article. (Both…

Zydus Cadila announced last week that its ZY19489 (MMV253) malaria radical cure, co-developed with the Medicines for Malaria Venture, has succeeded in Phase 1.

The Ahmedabad-based company said healthy volunteers in Australia safely received escalating doses of 25 to 1,500 mg of the oral antimalarial compound. An additional P. falciparum malaria human challenge trial showed no serious or severe drug-related adverse events.

The results demonstrate that ZY19489 has the potential to…

Bharat Biotech (BBIL), GSK and PATH issued a joint press release Wednesday announcing a technology transfer of GSK’s RTS,S malaria shot to the Hyderabad-based vaccine manufacturer.

The agreement transfers manufacturing of the RTS,S antigen and grants all rights to the malaria vaccine to BBIL, while GSK will continue to produce and supply the shot’s AS01E adjuvant.

GSK, development partner PATH and WHO have been looking for a long-term manufacturer in the event that ongoing pilots…

Mentions:

GSK and Novartis jointly pledged funding on Tuesday to research the link between genetic diversity and response to malaria and tuberculosis drugs in African patients.

A joint press release said the companies will invest a combined $3.6 million over five years in their Project Africa Genomic Research Approach for Diversity and Optimising Therapeutics (GRADIENT) collaboration, which will release all collected data to the public.

GRADIENT is inviting researchers across Africa to…

UK-based Exscientia announced last week a $4.2 million drug discovery grant from the Gates Foundation to use the company’s AI-driven platforms to find small molecule candidates for malaria, non-hormonal contraceptives and tuberculosis.

Exscientia has drug discovery collaborations with several companies, including Bayer, Bristol Myers Squibb, GSK and Sanofi.

Japan’s nonprofit Global Health Innovative Technology Fund (GHIT Fund) announced $2.2 million in drug development investments on Tuesday.

Three of the four awards support new projects for Chagas disease and malaria. The remaining award goes toward an ongoing drug discovery project between Takeda and Geneva-based Medicines for Malaria Venture.

GHIT Fund’s portfolio now includes 53 ongoing projects with $217 million invested so far, according to the press release.

Mentions:

Atlanta-based GeoVax announced Monday that it has signed a licensing agreement with the U.S. National Institute of Allergy and Infectious Diseases to support the company’s nonclinical development of vaccines against Ebola Sudan, Ebola Zaire, Lassa virus, malaria, Marburg virus and Zika virus, among other diseases.

The agreement—which also boosts the company’s oncology portfolio—gives GeoVax nonexclusive “access to certain materials and patent rights,” according to the press release.

An approved pediatric formulation of tafenoquine drew nearer last week after GSK and Medicines for Malaria Venture released new data showing that their single-dose radical cure for P. vivax malaria is safe and effective in children and adolescents ages 6 months to 15 years.

The Tafenoquine Exposure Assessment in Children (TEACH) study evaluated dosages of the oral 8-aminoquinoline drug based on weight, finding safety “consistent with previous clinical studies,” with 95% of subjects…

Mentions: